Cholangiocarcinoma

23 trials 9 recruiting MedDRA PT
23 Registered trials
9 Recruiting
20 Unique sponsors
29 Unique IMPs
16 Commercial trials
Drug classes (ATC)
— ATC code not specified 11
L Oncology (ATC L) 10
N Neurology/Psychiatry (ATC N) 1
V Various (ATC V) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 8 substances
Kinase inhibitor 5 substances
Topoisomerase I inhibitor 3 substances
Platinum compound 2 substances
Antimetabolite 2 substances
Monoclonal antibody (angiogenesis) 1 substance
Monoclonal antibody (chimeric) 1 substance
Immunosuppressant 1 substance
SERD 1 substance
Monoclonal antibody (tumor, humanized) 1 substance
Checkpoint inhibitor (PD-L1) 1 substance
Supportive / rescue 1 substance
EGFR inhibitor 1 substance
Checkpoint inhibitor (CTLA-4) 1 substance
Phase III: 6 Phase II: 9 Phase I/II: 1 Phase I: 4 Phase I (Other): 2 Phase I (First in Human): 1

Filter these 23 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 23 trials

Phase III

6 trials
  • AstraZeneca AB Commercial
    DURVALUMAB
    2023-507405-34-00 4 countries 2019 n=125
    Ended
  • Incyte Corp. Commercial
    CISPLATIN; GEMCITABINE; PEMIGATINIB
    2024-513513-12-00 8 countries 2019 n=110 Orphan
    Ended
  • Servier Affaires Medicales Commercial
    IMP not specified
    2022-501463-40-01 10 countries 2023 n=202
    Ended
  • Transthera Sciences (Nanjing) Inc. Commercial
    FLUOROURACIL; FOLINIC ACID; IRINOTECAN HYDROCHLORIDE; IRINOTECAN HYDROCHLORIDE TRIHYDRATE; OXALIPLATIN; TINENGOTINIB
    2023-505660-11-00 8 countries 2024 n=95
    Recruiting
  • Servier Affaires Medicales Academic
    IMP not specified
    2022-501463-40-00 4 countries n=65
    Not authorised
  • University Medical Center Hamburg-Eppendorf Academic
    IMP not specified
    2024-517340-61-00 4 countries 2024 n=573
    Ended

Phase II

9 trials
  • AstraZeneca AB Commercial
    BEVACIZUMAB; CISPLATIN; GEMCITABINE; INFLIXIMAB; LENVATINIB; MYCOPHENOLATE MOFETIL; RILVEGOSTOMIG; VOLRUSTOMIG
    2022-502317-29-00 2 countries 2023 n=60
    Ended
  • Lisata Therapeutics Inc. Commercial
    LSTA1
    2023-503740-14-00 1 country n=20
    Ended
  • Seagen Inc. Commercial
    FULVESTRANT; TRASTUZUMAB; TUCATINIB
    2024-511481-37-00 3 countries 2021 n=29
    Ended
  • Taiho Oncology Inc. Commercial
    FUTIBATINIB
    2023-503665-39-00 4 countries 2023 n=41 Orphan
    Recruiting
  • Centre Hospitalier Universitaire De Bordeaux Academic
    (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE; GALLIUM (68GA) CHLORIDE; GERMANIUM (68GE) CHLORIDE
    2024-517270-23-00 1 country 2026 n=120
    Recruiting
  • Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH Academic
    DURVALUMAB
    2024-511847-24-00 1 country 2022 n=40
    Ended
  • Heinrich-Heine-Universitaet Duesseldorf Academic
    IRINOTECAN; TRIFLURIDINE, TIPIRACIL HYDROCHLORIDE
    2024-517330-18-00 1 country 2025 n=38 Orphan
    Recruiting
  • IRCCS Istituto Nazionale Tumori Fondazione Pascale Academic
    CISPLATIN; GEMCITABINE
    2024-518656-23-00 1 country 2023 n=38
    Recruiting
  • Universitaetsklinikum Schleswig-Holstein AöR Academic
    DURVALUMAB; TREMELIMUMAB
    2024-515660-31-00 1 country 2023 n=31
    Ended

Phase I/II

1 trial
  • Institut De Recherches Internationales Servier IRIS Commercial
    CISPLATIN; DURVALUMAB; GEMCITABINE; IVOSIDENIB
    2024-514261-19-00 3 countries 2025 n=16 Orphan
    Recruiting

Phase I

4 trials
  • Adaptimmune LLC Commercial
    IMP not specified
    2024-514437-37-00 2 countries 2018 n=14
    Ended
  • BeOne Medicines AG Commercial
    IMP not specified
    2024-515307-19-00 3 countries 2025 n=79
    Recruiting
  • Immunocore Limited Commercial
    IMP not specified
    2023-509767-25-00 3 countries 2024 n=520
    Recruiting
  • Seagen Inc. Commercial
    IMP not specified
    2023-503389-22-00 4 countries 2022 n=147
    Ended

Phase I (Other)

2 trials
  • Hutchmed Ltd. Commercial
    IMP not specified
    2024-516370-30-00 1 country 2021 n=24
    Ended
  • Toray Industries Inc. Commercial
    IMP not specified
    2024-513915-28-00 1 country 2019 n=32
    Ended

Phase I (First in Human)

1 trial
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Seagen Inc. Commercial 2 Phase I, Phase II 0
AstraZeneca AB Commercial 2 Phase II, Phase III 0
Servier Affaires Medicales Commercial 2 Phase III 0
Adaptimmune LLC Commercial 1 Phase I 0
BeOne Medicines AG Commercial 1 Phase I 1
Immunocore Limited Commercial 1 Phase I 1
Hutchmed Ltd. Commercial 1 Phase I (Other) 0
Toray Industries Inc. Commercial 1 Phase I (Other) 0
Lisata Therapeutics Inc. Commercial 1 Phase II 0
Taiho Oncology Inc. Commercial 1 Phase II 1
Incyte Corp. Commercial 1 Phase III 0
Transthera Sciences (Nanjing) Inc. Commercial 1 Phase III 1
BioNTech SE Commercial 1 Phase I (First in Human) 1
Institut De Recherches Internationales Servier IRIS Commercial 1 Phase I/II 1
Centre Hospitalier Universitaire De Bordeaux Academic 1 Phase II 1
Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH Academic 1 Phase II 0
Heinrich-Heine-Universitaet Duesseldorf Academic 1 Phase II 1
IRCCS Istituto Nazionale Tumori Fondazione Pascale Academic 1 Phase II 1
Universitaetsklinikum Schleswig-Holstein AöR Academic 1 Phase II 0
University Medical Center Hamburg-Eppendorf Academic 1 Phase III 0
New trials by year
2019
3
2021
2
2022
2
2023
5
2024
3
2025
3
2026
2
← All indication landscapes